Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 0.7969 0.02 (2.57%) Market Cap: 203.80 Mil Enterprise Value: 36.36 Mil PE Ratio: 0 PB Ratio: 2.11 GF Score: 62/100

Full Year 2019 Adaptimmune Therapeutics PLC Earnings Call Transcript

Nov 06, 2019 / 01:00PM GMT
Release Date Price: $0.92 (-16.36%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to the Q3 2019 Adaptimmune Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the call over to Juli Miller. Please go ahead.

Juli P. Miller
Adaptimmune Therapeutics plc - Senior Director of IR

Good morning, and welcome to Adaptimmune's conference call to discuss our third quarter 2019 financial results and other business updates. We issued a press release earlier this morning, and I would ask you to please review the full text of our forward-looking statements there.

As a brief reminder, we anticipate making projections during this call and actual results could differ materially due to a number of factors, including those outlined in our latest filings with the SEC.

Adrian Rawcliffe, our Chief Executive Officer; and Elliot Norry, our acting Chief Medical Officer, are with me for the prepared portion of this call. Bill Bertrand, our Chief Operating Officer; Helen

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot